Breaking News


Dendreon Jumps as More Doctors Prescribe Cancer Therapy

Dendreon Corp. (DNDN) rose the most in nine months after announcing a third-quarter loss that was less than analysts’ estimates and saying more doctors are using its prostate cancer drug Provenge.

The biotechnology company jumped 16 percent to $4.47 at the close in New York, its biggest single-day advance since Feb. 6. The Seattle-based drugmaker had a loss of 33 cents a share, excluding a restructuring charge. Analysts had expected a loss of 82 cents, according to the average of 22 estimates compiled by Bloomberg.

Urologists prescribing Provenge grew 14 percent in the quarter, Dendreon said today in a statement. The number of oncologists doing so fell by less than 1 percent, an improvement from an 8 percent slide in the second quarter. The medicine accounted for two-thirds of Dendreon’s sales last year and faces competition from new drugs from Johnson & Johnson (JNJ) and Medivation Inc. (MDVN)

“We delivered strong growth in urology and have continued to improve results in oncology,” Chief Executive Officer John H. Johnson said in a statement today.

The quarter’s net loss of $154.9 million, or $1.04 a share, compared with a net loss of $147.1 million, or $1, a year earlier, Dendreon said.

To contact the reporter on this story: Alex Nussbaum in New York at

To contact the editor responsible for this story: Reg Gale at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.